What is Roivant Sciences?
Roivant Sciences is a biopharma company creation company serving providers, payers, patients, labs, hospitals, researchers, or life-sciences commercial teams.
- Category
- Biopharma company creation
- Headquarters
- New York, NY
- Founded
- See company profile and filings
- Employees
- Mid-market / scaled operating company
- Total funding
- Public company
- Status
- Public company; Nasdaq: ROIV
What is Roivant Sciences?
Roivant Sciences is a biopharma company creation company headquartered in New York, NY.
Roivant Sciences operates in biopharma company creation and has reached a scaled mid-market profile rather than an early startup footprint. Its official site and investor/company materials position the business around Vants, Immunology, Dermatology, with customers using the company for repeatable operating workflows rather than one-off projects.
For sellers, Roivant Sciences is useful to profile because the buying center is large enough to include specialized finance, IT, operations, procurement, and line-of-business owners. The company status is Public company; Nasdaq: ROIV, so the best live signals are current company announcements, investor materials where available, hiring patterns, product launches, and partner ecosystem activity.
What does Roivant Sciences offer?
Roivant Sciences's profile centers on Vants, Immunology, Dermatology, FcRn programs.
- Vants· Biopharma company creation
- Immunology· Biopharma company creation
- Dermatology· Biopharma company creation
- FcRn programs· Biopharma company creation
- Technology-enabled development· Biopharma company creation
- Portfolio company building· Biopharma company creation
How does Roivant Sciences make money?
Roivant Sciences makes money through commercial activity tied to biopharma company creation.
Roivant Sciences monetizes through the commercial model common to biopharma company creation: a mix of product sales, subscriptions, usage, services, channel programs, or transaction volume depending on the operating unit. Public list pricing is not always available, so enterprise buyers usually evaluate packaging, contract scope, geographic coverage, implementation services, and support commitments.
The practical growth levers are account expansion, new product attach, channel reach, retention, and operational efficiency. For outbound teams, that means relevant sales angles usually connect to productivity, integration, compliance, data quality, margin improvement, customer experience, or faster execution across distributed teams.
Who leads Roivant Sciences?
Roivant Sciences's named executives should be verified on the official leadership or investor-relations page before outreach.
- Roivant Sciences executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Roivant Sciences finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- Roivant Sciences technology or operations leadershipTechnology, product, operations, or security leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact Roivant Sciences's leadership?
Roivant Sciences should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://roivant.com- Roivant Sciences investor relationsInvestor relations / corporate contactcontact via https://roivant.com
- Roivant Sciences media relationsMedia or communications contact routecontact via https://roivant.com
How is Roivant Sciences funded?
Roivant Sciences's current status is Public company; Nasdaq: ROIV.
Roivant Sciences's current capital profile is best understood through its current status: Public company; Nasdaq: ROIV. If the company is public, the relevant financing signals are annual reports, quarterly results, debt disclosures, buybacks, acquisitions, and capital allocation commentary rather than venture rounds.
If the company is private or recently acquired, the important seller signal is ownership context: sponsors or strategic owners often push standardization, operating metrics, procurement discipline, and integration work. In either case, budget timing should be inferred from current company announcements, earnings materials, product launches, hiring, and strategic initiatives rather than stale funding databases.
How did Roivant Sciences get here?
Roivant Sciences's history should be read through founding, scale-up, public/private ownership, and current product or market focus.
- FoundingRoivant Sciences is foundedThe company begins building in biopharma company creation.
- Scale-upCommercial footprint expandsRoivant Sciences broadens its product, customer, or geographic reach.
- Capital marketsPublic company; Nasdaq: ROIVOwnership and financing context shapes procurement, reporting, and operating priorities.
- 2025Mid-market operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, current status, and public source references.
Who are Roivant Sciences's competitors?
Roivant Sciences competes with larger platform incumbents and focused specialists in biopharma company creation.
- MedtronicGlobal medical-technology incumbent with broad device and care-management scale.
- Boston ScientificLarge medical-device company competing across interventional specialties.
- AbbottHealthcare company with diagnostics, diabetes care, devices, and nutrition scale.
- Johnson & Johnson MedTechLarge medtech and pharmaceutical incumbent with global commercial reach.
- StrykerOrthopedics, neurotechnology, and surgical equipment competitor with hospital relationships.
Roivant Sciences — frequently asked questions
